World Health Organization. Global tuberculosis report 2015, 20th ed. World Health Organization. http://www.who.int/iris/handle/10665/191102.
International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels: International Diabetes Federation; 2015.
Google Scholar
Kim SJ, Hong YP, Lew WJ, et al. Incidence of pulmonary tuberculosis among diabetics. Tuber Lung Dis. 1995;76:529–33.
Article
PubMed
CAS
Google Scholar
Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55:19–26.
Article
PubMed
Google Scholar
Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5:e152.
Article
PubMed
PubMed Central
Google Scholar
Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.
Article
PubMed
PubMed Central
Google Scholar
Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9:737–46.
Article
PubMed
PubMed Central
Google Scholar
Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams textbook of endocrinology. Philadelphia: Elsevier Health Sciences; 2015.
Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs. 2003;63:535–53.
Article
PubMed
CAS
Google Scholar
Chaulet P. Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities. Int J Tuberc Lung Dis. 1999;3:S353–7. discussion S81–7
PubMed
CAS
Google Scholar
Blomberg B, Spinaci S, Fourie B, et al. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ. 2001;79:61–8.
PubMed
PubMed Central
CAS
Google Scholar
Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet. 2012;51:481–99.
Article
PubMed
CAS
Google Scholar
Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006;43:848–54.
Article
PubMed
CAS
Google Scholar
Heysell SK, Moore JL, Staley D, et al. Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA. Tuberc Res Treat. 2013;2013:129723.
PubMed
PubMed Central
Google Scholar
Medellín-Garibay SE, Cortez-Espinosa N, Milán-Segovia RC, et al. Clinical pharmacokinetics of rifampin in patients with tuberculosis and type 2 diabetes mellitus: association with biochemical and immunological parameters. Antimicrob Agents Chemother. 2015;59:7707–14.
Article
PubMed
PubMed Central
CAS
Google Scholar
Association AD. 7. Approaches to Glycemic Treatment. Diabetes Care. 2016;39(Suppl 1):S52–9.
Google Scholar
Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014;6:263ra159.
Article
PubMed
CAS
Google Scholar
Chang MJ, Chae JW, Yun HY, et al. Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis (Edinb). 2015;95:54–9.
Article
CAS
Google Scholar
Albanna AS, Smith BM, Cowan D, et al. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J. 2013;42:721–32.
Article
PubMed
CAS
Google Scholar
Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, et al. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2016;5:CD009913.
Google Scholar
Zhang LX, Kan GQ, Tu DH, Wan LY, Faruqi AR. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. Curr Ther Res. 1996;57(11):849–56.
Article
CAS
Google Scholar
Zaka-Ur-Rehman Z, Jamshaid M, Chaudhry A. Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients. Pak J Pharm Sci. 2008;21:185–94.
PubMed
CAS
Google Scholar
Wu JT, Chiu CT, Wei YF, et al. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. Clinics (Sao Paulo). 2015;70:429–34.
Article
Google Scholar
Su WJ, Perng RP. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis. 2002;6:1029–32.
PubMed
CAS
Google Scholar
Bartacek A, Schütt D, Panosch B, et al. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009;13:760–6.
PubMed
CAS
Google Scholar
Lienhardt C, Cook SV, Burgos M, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the study C randomized controlled trial. JAMA. 2011;305:1415–23.
Article
PubMed
CAS
Google Scholar
Association AD. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2016;39(Suppl 1):S13–22.
Google Scholar
Global Laboratory Initiative. Mycobacteriology laboratory manual. 1st ed. Global Laboratory Initiative. World Health Organization: Geneva. 2014.
Al-Shaer MH, Mansour H, Elewa H, Salameh P, Iqbal F. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC Infect Dis. 2017;17(1):118.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464–73.
Article
PubMed
PubMed Central
CAS
Google Scholar
Alkabab Y, Keller S, Dodge D, Houpt ER, Staley D, Heysell SK. Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC Infect Dis. 2017;17:125.
Article
PubMed
PubMed Central
Google Scholar
Gravendeel JM, Asapa AS, Becx-Bleumink M, et al. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis (Edinb). 2003;83:183–6.
Article
Google Scholar
Morgan MA, Horstmeier CD, DeYoung DR, Roberts GD. Comparison of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol. 1983;18(2):384–8.
PubMed
PubMed Central
CAS
Google Scholar
Al-Moamary MS, Black W, Bessuille E, Elwood RK, Vedal S. The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. Chest. 1999;116(3):726–31.
Article
PubMed
CAS
Google Scholar
Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231–79.
PubMed
CAS
Google Scholar